An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)

• Status: Active, not recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Crizotinib

Criteria

Inclusion Criteria:

• histologically or cytologically proven diagnosis of malignancy other than NSCLC

• positive for translocation or inversion event involving the ALK gene locus

• positive for ALK amplification events

• positive for ALK activating point mutations

Exclusion Criteria:

• mutations of amplifications involving the c-Met gene but not the ALK gene

• concurrent treatment on another therapeutic clinical trial

• prior therapy specifically directed against ALK